LivaNova has completed the CORE-VNS study, assessing outcomes via real-world evidence on the use of the VNS Therapy device in ...

First-time seizures in adults could be caused by a stroke, metabolic imbalances, or brain injury. Learn about why seizures ...

A Carlisle man who battled with addiction since the age of 13 was found dead due to drug use in his home, an inquest has heard. Mark Pilling, 45, was found dead by his partner in his home on Partridge ...

TRIBUTES have been paid to a young Flintshire man following his tragic death from epilepsy. Jamie, from Oakenholt, died suddenly at the age of just 25 due to an epileptic seizure which led to cardiac ...

Cecilia, who suffers from blood cancer, claims her home has so many issues she’s been forced to eat McDonalds ‘to survive’ ...

Eamonn started playing rugby when he was six years old and now plays in the second and third team for Huel Tring Rugby.

Empatica announced today that it received CE mark approval for its EpiMonitor epilepsy monitoring solution. EpiMonitor, a ...

NeuroPace has reported the initial primary endpoint one-year outcomes from the NAUTILUS trial of the RNS System.

Following its successful US launch and FDA clearance, Empatica is proud to announce that EpiMonitor, its pioneering epilepsy ...

NeuroPace's RNS System trial showed a strong safety profile and subgroup efficacy in drug-resistant epilepsy, prompting FDA ...

Shares of NeuroPace Inc (NASDAQ:NPCE) plummeted 36.1% today after the company reported that its primary effectiveness endpoint for the NAUTILUS study did not reach statistical significance in the ...

Shares of NeuroPace sank after the company said the study of its RNS system for treating drug-resistant idiopathic generalized epilepsy missed a primary endpoint. The stock was down 37% at $11.15 in ...